CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 80 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3 | -99.9% | 3,800 | +533.3% | 0.00% | – |
| Q3 2020 | $4,000 | +100.0% | 600 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | +100.0% | 600 | -45.5% | 0.00% | – |
| Q1 2020 | $1,000 | -50.0% | 1,100 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | -60.0% | 1,100 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | -90.2% | 1,100 | -94.3% | 0.00% | -100.0% |
| Q2 2019 | $51,000 | +466.7% | 19,400 | +1041.2% | 0.00% | +300.0% |
| Q1 2019 | $9,000 | -50.0% | 1,700 | -29.2% | 0.00% | -50.0% |
| Q4 2018 | $18,000 | – | 2,400 | -11.1% | 0.00% | – |
| Q3 2018 | $0 | -100.0% | 2,700 | -50.0% | 0.00% | – |
| Q2 2018 | $5,000 | -58.3% | 5,400 | +315.4% | 0.00% | -100.0% |
| Q1 2018 | $12,000 | +200.0% | 1,300 | +44.4% | 0.00% | – |
| Q4 2017 | $4,000 | – | 900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |